Back to Authors

Piazza, Fabio Di

https://orcid.org/0000-0003-4027-4156

Mayo Clinic

Medtronic (Italy)

Citations 2

Frequency and Temporal Distribution of Postoperative Respiratory Depressive Events
Driver, Christine , Laporta, Mariana L. , Piazza, Fabio Di , Overdyk, Frank J. , Driver, C Noelle, Driver, C. Noelle, Bergese, Sergio D. , Urman, Richard D , Šprung, Juraj , Weingarten, Toby N.

Anesthesia & Analgesia | April 17, 2021 | Volume: 132 | Issue: 5 | Pages: 1206-1214

10.1213/ane.0000000000005478 Get It

BACKGROUND: The frequency and temporal distribution of postoperative respiratory depression (RD) events are not completely understood. This study determined the temporal distribution and frequency of RD episodes in postsurgical patients continuously monitored by bedside capnography and pulse oximetry. METHODS: This was a post hoc study of a subset of postsurgical patients enrolled in The PRediction of Opioid-induced respiratory Depression In patients monitored by capnoGraphY (PRODIGY) trial from 2 sites in the United States. These patients had undergone continuous bedside monitoring on general care wards. These data were adjudicated for potential RD episodes. The number of RD episodes per patient and the time of each RD episode were determined. The first RD episode experienced by a patient was classified as an “initial” episode, and the initial and all subsequent RD episodes experienced by a patient were classified as “all” episodes. A PRODIGY risk score was calculated. RESULTS: Data analyzed from 250 patients contained 2539 RD episodes in 155 (62.0%, 95% confidence interval, 55.7-68.0) patients with median 2 [0–8], range of 0–545 RD episodes per patient, with a PRODIGY risk score distribution of 100 (40.0%) low, 79 (31.6%) intermediate, 70 (28.0%) high (missing data from 1 patient). Median time to the initial RD episode was 8.8 [5.1–18.0] hours postoperatively. There was a peak occurrence of initial RD events between 14:00 and 20:00 on the day of surgery, and these were associated with a large number of subsequent events in the same timeframe. The peak time of all RD episodes occurred from 02:00 to 06:00. Patients with high PRODIGY risk scores had higher incidence and greater number of RD episodes per patient ( P < .001, overall comparisons between groups for both incidence [χ 2 ] and number of episodes [Kruskal-Wallis test]). CONCLUSIONS: Continuous monitoring of surgical patients demonstrates that RD episodes are common, and risk increases with higher PRODIGY scores. In this patient cohort, the rate of initial RD episodes peaked in the afternoon to early evening, while peak rate of all RD episodes occurred in early morning. Further, among patients with RD episodes, the number of episodes increased with higher PRODIGY scores.
Cryoballoon ablation vs. antiarrhythmic drugs: first-line therapy for patients with paroxysmal atrial fibrillation
Kuniss, Malte , Pavlović, Nikola , Hermida, J S, Healey, Stewart, Arena, Giuseppe , Badenco, Nicolas , Meyer, Christian , Chen, Jian , Iacopino, Saverio , Anselme, Frédéric , Packer, Douglas L. , Pitschner, Heinz-Friedrich, Asmundis, Carlo de , Willems, Stephan , Piazza, Fabio Di , Becker, Daniel , Chierchia, Gian‐Battista , Investigators, for the Cryo-FIRST, Meyer, Christian , Anselme, Frédéric , deAsmundis, Carlo , Velagić, Vedran , Investigators, for the Cryo-FIRST

EP Europace | January 25, 2021 | Volume: 23 | Issue: 7 | Pages: 1033-1041

10.1093/europace/euab029 Get It

AbstractAimsTreatment guidelines for patients with atrial fibrillation (AF) suggest that patients should be managed with an antiarrhythmic drug (AAD) before undergoing catheter ablation (CA). This study evaluated whether pulmonary vein isolation employing cryoballoon CA is superior to AAD therapy for the prevention of atrial arrhythmia (AA) recurrence in rhythm control naive patients with paroxysmal AF (PAF).Methods and resultsA total of 218 treatment naive patients with symptomatic PAF were randomized (1 : 1) to cryoballoon CA (Arctic Front Advance, Medtronic) or AAD (Class I or III) and followed for 12 months. The primary endpoint was ≥1 episode of recurrent AA (AF, atrial flutter, or atrial tachycardia) &gt;30 s after a prespecified 90-day blanking period. Secondary endpoints included the rate of serious adverse events (SAEs) and recurrence of symptomatic palpitations (evaluated via patient diaries). Freedom from AA was achieved in 82.2% of subjects in the cryoballoon arm and 67.6% of subjects in the AAD arm (HR = 0.48, P = 0.01). There were no group differences in the time-to-first (HR = 0.76, P = 0.28) or overall incidence [incidence rate ratio (IRR)=0.79, P = 0.28] of SAEs. The incidence rate of symptomatic palpitations was lower in the cryoballoon (7.61 days/year) compared with the AAD arm (18.96 days/year; IRR = 0.40, P &lt; 0.001).ConclusionsCryoballoon CA was superior to AAD therapy, significantly reducing AA recurrence in treatment naive patients with PAF. Additionally, cryoballoon CA was associated with lower symptom recurrence and a similar rate of SAEs compared with AAD therapy.